First patient in treatment in RhoVac's clinical phase IIb study in the USA
RhoVac AB ("RhoVac") announces today, August 10th 2020, that the first patient in the USA is included in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac").The first patient in the USA is included in RhoVac’s clinical phase IIb study, called BRaVac. The first US clinic to include a patient in the study was Carolina Urologic Research Center. BraVac is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced